



Case Study Story: MedRhythms in Portland, ME

As a fellow at Spaulding Rehabilitation Hospital in Boston, Brian Harris implemented the first full-time, inpatient neurologic music therapy program. In 2015, Harris expanded that program into a business. With Owen McCarthy, Harris co-founded MedRhythms, a digital health startup that combines sensors, software, and music with advanced neuroscience to restore nervous system functions and develop therapeutics across a range of conditions.

But for Harris and McCarthy, Boston was temporary. In 2016, they moved MedRhythms' headquarters from Boston to Portland, Maine. Harris and McCarthy had both grown up in Maine and attended the University of Maine, and they know better than anyone the benefits of the Pine Tree State. As Harris puts it, "Being in Maine, we are just an hour and a half away from downtown Boston. We have the best of both worlds."

"We cared about Maine and wanted to build an iconic company here. We had great support from the ecosystem and from the state of Maine."

—Brian Harris, CEO & Co-Founder of MedRhythms

Notably, MedRhythms found their footing through Maine-based financial incentives. The company was initially financed by grants from the Maine Technology Institute (MTI) and investment from the Maine Venture Fund and Finance Authority of Maine (FAME).

Since then, MedRhythms has grown to 44 employees and has raised a total of \$43 million from both angel and venture capital investors. Just this summer, their evidence-based neurorehabilitation to improve walking and ambulation for people with chronic stroke, InTandem™, was listed as a Class II, Rx-only medical device with the FDA.



Move to Maine, and see what can happen.



2015

Brian Harris and Owen McCarthy found MedRhythms in Boston.



2016

MedRhythms moves its headquarters from Boston, MA to Portland, ME.



2018

MedRhythms raises \$5 million in an oversubscribed Series A Financing round.



2021

MedRhythms obtains \$27 million in Series B venture capital funding.



2023

MedRhythms' neurorehabilitation system InTandem™ is listed as a Class II medical device with the FDA